The need to decipher various biological events has led to the elucidation of the molecular mechanisms underlying a number of disease processes. Consequently, the detection and simultaneous monitoring of chemical interactions between biological targets has become indispensable in medical diagnosis, targeted therapeutics, and molecular biology. Multiplexed applications employing nanomaterials, which represent the integration of nanotechnology and biology, have changed the bioanalytical outlook and provided various promising tools. Among these nanomaterials, fluorescent dye-doped silica nanoparticles have demonstrated excellent potential for use in advanced bioanalysis to facilitate deeper understanding of biology and medicine at the molecular level. In particular, silica nanoparticles have been applied to diagnostics and therapeutic applications in cancer and gene/drug delivery. This feature article summarizes recent developments in the synthesis, biocompatibility, and bioapplications of fluorescent dye-doped silica nanoparticles.

Recently, significant advances have been made independently in electrogenerated chemiluminescence (ECL) analysis and supramolecular anion sensing. Herein, we demonstrate a new proof of concept for ECL-based pyrophosphate (PPi) sensing, where the emission intensity is changed by electrochemical turn-on. The ECL PPi sensor (1-2Zn) consists of two orthogonally bonded moieties: boron dipyrromethene (ECL reporter) and a phenoxo-bridged bis(Zn(2+)-dipicolylamine) complex (PPi receptor). The presence of PPi is confirmed from the change in the intensity of green ECL generated from the former when PPi is selectively recognized by the latter. During PPi recognition, changes are caused in the electronic states of the receptor, and this stimulates the attenuation of ECL intensity. The electrochemical "on-off" triggering of light emission upon anion binding forms the basis of a new anion sensing strategy. We expect that green-colored ECL sensing would offer an advantage to current ECL analysis.

Hormone-specific anticancer drugs for breast cancer treatment can cause serious side effects. Thus, treatment with natural compounds has been considered a better approach as this minimizes side effects and has multiple targets. 6-Gingerol is an active polyphenol in ginger with various modalities, including anticancer activity, although its mechanism of action remains unknown. Increases in the level of reactive oxygen species (ROS) can lead to DNA damage and the induction of DNA damage response (DDR) mechanism, leading to cell cycle arrest apoptosis and tumorsphere suppression. Epidermal growth factor receptor (EGFR) promotes tumor growth by stimulating signaling of downstream targets that in turn activates tumor protein 53 (p53) to promote apoptosis. Here we assessed the effect of 6-gingerol treatment on MDA-MB-231 and MCF-7 breast cancer cell lines. 6-Gingerol induced cellular and mitochondrial ROS that elevated DDR through ataxia-telangiectasia mutated and p53 activation. 6-Gingerol also induced G0/G1 cell cycle arrest and mitochondrial apoptosis by mediating the BAX/BCL-2 ratio and release of cytochrome c. It also exhibited a suppression ability of tumorsphere formation in breast cancer cells. EGFR/Src/STAT3 signaling was also determined to be responsible for p53 activation and that 6-gingerol induced p53-dependent intrinsic apoptosis in breast cancer cells. Therefore, 6-gingerol may be used as a candidate drug against hormone-dependent breast cancer cells.

Recently, natural compounds have been used globally for cancer treatment studies. Silibinin is a natural compound extracted from Silybum marianum (milk thistle), which has been suggested as an anticancer drug through various studies. Studies on its activity in various cancers are undergoing. This study demonstrated the molecular signaling behind the anticancer activity of silibinin in non-small cell lung cancer (NSCLC). Quantitative real-time polymerase chain reaction and Western blotting analysis were performed for molecular signaling analysis. Wound healing assay, invasion assay, and in vitro angiogenesis were performed for the anticancer activity of silibinin. The results indicated that silibinin inhibited A549, H292, and H460 cell proliferation in a concentration-dependent manner, as confirmed by the induction of G0/G1 cell cycle arrest and apoptosis and the inhibition of tumor angiogenesis, migration, and invasion. This study also assessed the role of silibinin in suppressing tumorsphere formation using the tumorsphere formation assay. By binding to the epidermal growth factor receptor (EGFR), silibinin downregulated phosphorylated EGFR expression, which then inhibited its downstream targets, the JAK2/STAT5 and PI3K/AKT pathways, and thereby reduced matrix metalloproteinase, PD-L1, and vascular endothelial growth factor expression. Binding analysis demonstrated that STAT5 binds to the PD-L1 promoter region in the nucleus and silibinin inhibited the STAT5/PD-L1 complex. Altogether, silibinin could be considered as a candidate for tumor immunotherapy and cancer stem cell-targeted therapy.

No abstract